Janux Therapeutics, Inc.
Business
Janux Therapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies using proprietary TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator) platforms designed to activate the immune system against tumors while minimizing toxicity. Lead programs include JANX007, a PSMA-targeted TRACTr in Phase 1 for metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeted TRACTr in Phase 1 for solid tumors, alongside JANX011, a CD19-ARM in Phase 1 for autoimmune diseases. The company has strategic collaborations with Merck and Bristol Myers Squibb for additional TRACTr development.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 10 | 11 | 8 | 9 | 4 | |
| Research and development | 126 | 68 | 55 | 53 | 26 | |
| General and administrative | 42 | 41 | 26 | 22 | 10 | |
| Total operating expenses | 168 | 109 | 81 | 76 | 37 | |
| Loss from operations | −158 | −99 | −73 | −67 | −33 | |
| Interest income | 44 | 30 | 15 | 4 | 257,000 | |
| Total other income | 44 | 30 | 15 | 4 | 257,000 | |
| Net loss | −114 | −69 | −58 | −63 | −33 | |
| Unrealized gain on available-for-sale securities, net | 2 | 1 | 2 | −1 | −270,000 | |
| Comprehensive loss | −111 | −67 | −56 | −64 | −33 | |
| Net loss per common share, basic | −1.83 | −1.28 | −1.32 | −1.52 | −1.39 | |
| Net loss per common share, diluted | −1.83 | −1.28 | −1.32 | −1.52 | −1.39 | |
| Weighted-average shares of common stock outstanding, basic | 62 | 54 | 44 | 41 | 24 | |
| Weighted-average shares of common stock outstanding diluted | 62 | 54 | 44 | 41 | 24 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 52 | 431 | 19 | 51 | 36 | |
| Short-term investments | 914 | 595 | 325 | 276 | 339 | |
| Prepaid expenses and other current assets | 9 | 8 | 5 | 5 | 2 | |
| Total current assets | 976 | 1,034 | 349 | 332 | 377 | |
| Restricted cash | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | |
| Property and equipment, net | 4 | 5 | 7 | 7 | 1 | |
| Operating lease right-of-use assets | 18 | 19 | 21 | 22 | 185,000 | |
| Other long-term assets | 3 | 3 | 3 | 1 | 392,000 | |
| Total assets | 1,002 | 1,062 | 380 | 364 | 380 | |
| Accounts payable | 5 | 4 | 2 | 2 | 2 | |
| Accrued expenses | 18 | 12 | 7 | 8 | 4 | |
| Current portion of operating lease liabilities | 2 | 2 | 2 | 763,000 | 194,000 | |
| Total current liabilities | 25 | 17 | 13 | 17 | 13 | |
| Operating lease liabilities, net of current portion | 20 | 21 | 23 | 25 | 0 | |
| Total liabilities | 45 | 39 | 36 | 43 | 13 | |
| Commitments and contingencies (Note 3) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; authorized shares - 10,000,000 at December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.001 par value; authorized shares - 200,000,000 at December 31, 2025 and 2024, respectively; issued shares - 60,384,283 and 59,064,606 at December 31, 2025 and 2024, respectively; outstanding shares - 60,384,283 and 59,064,606 at December 31, 2025 and 2024, respectively | 60,000 | 59,000 | 46,000 | 42,000 | 41,000 | |
| Additional paid-in capital | 1,304 | 1,258 | 512 | 433 | 414 | |
| Accumulated other comprehensive income | 4 | 2 | 665,000 | −2 | −270,000 | |
| Accumulated deficit | −351 | −238 | −169 | −110 | −47 | |
| Total stockholders' equity | 957 | 1,023 | 344 | 321 | 366 | |
| Total liabilities and stockholders' equity | 1,002 | 1,062 | 380 | 364 | 380 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 2 | 2 | 2 | 841,000 | 113,000 | |
| Stock-based compensation | 40 | 33 | 20 | 17 | 7 | |
| Accretion of discounts on investments, net | −18 | −11 | −8 | −2 | −172,000 | |
| Prepaid expenses and other current assets | −827,000 | −3 | 210,000 | −3 | −2 | |
| Other long-term assets | 276,000 | −375,000 | −1 | −1 | −392,000 | |
| Accounts payable | 977,000 | 2 | 277,000 | −294,000 | 2 | |
| Accrued expenses | 6 | 4 | −678,000 | 4 | 3 | |
| Deferred revenue | 0 | −2 | −6 | 2 | −2 | |
| Operating lease right-of-use assets and liabilities, net | −2,000 | 35,000 | 678,000 | 3 | 9,000 | |
| Net cash used in operating activities | −82 | −44 | −51 | −43 | −17 | |
| Purchases of property and equipment | −1 | −359,000 | −2 | −6 | −1 | |
| Purchases of short-term investments | −705 | −471 | −317 | −294 | −474 | |
| Maturities of short-term investments | 405 | 213 | 278 | 359 | 134 | |
| Net cash used in investing activities | −301 | −258 | −41 | 58 | −341 | |
| Proceeds from exercise of common stock options and employee stock purchase plan | 5 | 15 | 3 | 500,000 | — | |
| Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | −347,000 | 698 | 57 | 0 | — | |
| Net cash provided by financing activities | 5 | 713 | 60 | 500,000 | 387 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | −378 | 411 | −32 | 16 | 29 | |
| Unpaid property and equipment | 0 | 6,000 | 132,000 | 109,000 | 38,000 | |
| Unpaid issuance costs | 0 | 347,000 | 0 | 0 | — | |
| Vesting of restricted common stock | 0 | 20,000 | 149,000 | 1 | 475,000 | |
| Operating lease liabilities arising from right-of-use assets | 943,000 | 0 | 0 | 23 | 256,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Janux Therapeutics, Inc.'s CIK number?
Janux Therapeutics, Inc.'s SEC CIK number is 0001817713 (1817713). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Janux Therapeutics, Inc.'s SEC filings?
All of Janux Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Janux Therapeutics, Inc. last report earnings?
Janux Therapeutics, Inc. (JANX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211964). This is Janux Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Janux Therapeutics, Inc.'s most recent earnings 8-K?
Janux Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211964. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Janux Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →